Influence of unrecognized molecular heterogeneity on randomized clinical trials

Journal of Clinical Oncology

Volumn 20, Issue 10, 2002, Pages 2495-2499

  Betensky, Rebecca A ^a   Louis, David N ^a   Cairncross, J Gregory ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; GENETIC HETEROGENEITY; HISTOLOGY; HUMAN; PRIORITY JOURNAL; RELIABILITY; SOLID TUMOR; TREATMENT PLANNING;

BIAS (EPIDEMIOLOGY); DRUG RESISTANCE; FALSE NEGATIVE REACTIONS; GENETIC HETEROGENEITY; HUMANS; MOLECULAR BIOLOGY; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS; PHILOSOPHY; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 0037093249     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.06.140     Document Type: Article

References (18)

1. Molecular portraits of human breast tumours
2. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
3. Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis
4. Biased estimates of treatment effect in randomized experiments with nonlinear regressions and omitted covariates
5. Effect of misspecification of regression models in the analysis of survival data
6. Misspecified proportional hazard models
7. A quantitative study of the bias in estimating the treatment effect caused by omitting a balanced covariate in survival models
8. Effects of omitting covariates in Cox's model for survival data
9. Effects of covariate omission and categorization when analysing randomized trials with the Cox model
10. Properties of proportional-hazards score tests under misspecified regression models
11. Clinical trials in the genomic era: Effects of protective genotypes on sample size and duration of trial
12. The asymptotic properties of nonparametric tests for comparing survival distributions
13. Assessing apparent treatment: Covariate interactions in randomized clinical trials
14. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
15. Age influences chemotherapy response in astrocytomas
16. Proliferation index is related to patient age in glioblastoma
17. The use of simulation and bootstrap in information-based group sequential studies
18. Designed extension of studies based on conditional power